Center for Biologics Evaluation and Research

Results: 1843



#Item
111Summary Basis for Regulatory Action Date: October 28, 2014 From: Timothy A. Fritz, PhD, Review Committee Chair BLA/ STN#: [removed]Applicant Name: Protein Sciences Corporation Date of Submission: October 21, 2013

Summary Basis for Regulatory Action Date: October 28, 2014 From: Timothy A. Fritz, PhD, Review Committee Chair BLA/ STN#: [removed]Applicant Name: Protein Sciences Corporation Date of Submission: October 21, 2013

Add to Reading List

Source URL: www.fda.gov

Language: English
112Summary Basis for Regulatory Action Date: October 30, 2014 From: CDR Edward W. Wolfgang, MSA, Chair of the Review Committee BLA/ STN: [removed]Applicant Name: Sanofi Pasteur Inc. Date of Submission: December 30, 2013

Summary Basis for Regulatory Action Date: October 30, 2014 From: CDR Edward W. Wolfgang, MSA, Chair of the Review Committee BLA/ STN: [removed]Applicant Name: Sanofi Pasteur Inc. Date of Submission: December 30, 2013

Add to Reading List

Source URL: www.fda.gov

Language: English
113FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH CELLULAR, TISSUE AND GENE THERAPIES ADVISORY COMMITTEE Meeting #61, November 6, 2014 CITED PUBLICATIONS Couch et al., The minimal infectious dose

FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH CELLULAR, TISSUE AND GENE THERAPIES ADVISORY COMMITTEE Meeting #61, November 6, 2014 CITED PUBLICATIONS Couch et al., The minimal infectious dose

Add to Reading List

Source URL: www.fda.gov

Language: English
114Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology ___________________________________________________ MEMORANDUM

Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology ___________________________________________________ MEMORANDUM

Add to Reading List

Source URL: www.fda.gov

Language: English
115Guidance for Industry: Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Prod

Guidance for Industry: Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Prod

Add to Reading List

Source URL: www.fda.gov

Language: English
116Guidance for Industry: Compliance with 21 CFR Part[removed]c)(1) – Manufacturing Arrangements

Guidance for Industry: Compliance with 21 CFR Part[removed]c)(1) – Manufacturing Arrangements

Add to Reading List

Source URL: www.fda.gov

Language: English
117Guidance for Industry:  Efficacy Studies to Support Marketing of Fibrin Sealant Products Manufactured for Commercial Use

Guidance for Industry: Efficacy Studies to Support Marketing of Fibrin Sealant Products Manufactured for Commercial Use

Add to Reading List

Source URL: www.fda.gov

Language: English
118Same Surgical Procedure Exception under 21 CFR[removed]b): Questions and Answers Regarding the Scope of the Exception Draft Guidance for Industry DRAFT GUIDANCE

Same Surgical Procedure Exception under 21 CFR[removed]b): Questions and Answers Regarding the Scope of the Exception Draft Guidance for Industry DRAFT GUIDANCE

Add to Reading List

Source URL: www.fda.gov

Language: English
119Proposed Approach to Regulation of Cellular and Tissue Based Products

Proposed Approach to Regulation of Cellular and Tissue Based Products

Add to Reading List

Source URL: www.fda.gov

Language: English
120Electronic Postmarket Safety Reporting Updates FDA E2B (R3) Implementation, Planning and Tools  Lise R. Stevens

Electronic Postmarket Safety Reporting Updates FDA E2B (R3) Implementation, Planning and Tools Lise R. Stevens

Add to Reading List

Source URL: www.fda.gov

Language: English